Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Inflammatory Bowel Disease
•
General Rheumatology
•
Gastroenterology
•
Biosimilars
Do we need to be concerned about immunogenicity and effectiveness of biosimilars in patients who may need to switch multiple times due to insurance reasons?
Related Questions
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
How would you manage a patient with Crohn's disease on a biologic and presents with non-bloody diarrhea, normal-appearing mucosa on sigmoidoscopy but severe colitis on biopsy with a positive CMV stain?
Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
